Stromal cells from endometriotic lesions and endometrium from women with endometriosis have reduced decidualization capacity


a Nuffield Department of Obstetrics and Gynaecology, The Women's Centre, John Radcliffe Hospital, Oxford, United Kingdom

b Department of Obstetrics and Gynaecology, University Hospital Gasthuisberg, Herestraat Leuven, Belgium

Abstract

Objective—To evaluate the phenotype, proliferative, and differentiation capacities in vitro of stromal cells derived from peritoneal, ovarian, and deeply infiltrating endometriosis.

Design—Experimental study using phase contrast microscopy, immunocytochemistry, and functional bioassays.

Setting—University-based laboratory.

Patient(s)—Women with and without endometriosis undergoing surgery for benign indications.

Intervention(s)—None.

Main Outcome Measure(s)—The stability in vitro of stromal cells derived from peritoneal (n = 18), ovarian (n = 29), and deeply infiltrating (n = 14) endometriotic lesions, as well as endometrium from women with (n = 5) and without endometriosis (n = 5) was evaluated by detection of endometrial markers. The proliferative and differentiation capacity of the cells was assessed by the use of cell doubling estimation and in vitro decidualization assays.

Result(s)—The expression of the progesterone receptor and CD10 in stromal cells derived from the three types of endometriotic lesions is retained in culture up to passage 10. The doubling time of stromal cells from deeply infiltrating lesions is lower than that of endometrial stromal cells. Levels of prolactin and insulin-like growth factor binding protein-1 (IGFBP-1) are reduced in supernatants from stromal cells derived from the three types of lesions and from the endometrium of women with endometriosis.

Conclusion(s)—The peritoneal, ovarian, and deeply infiltrating endometriotic stromal cell lines we describe retain in vivo tissue markers. Loss of differentiation capacity of the endometriotic cell lines and endometrial cells from women with endometriosis may influence the capacity for proliferation and survival of these cells in the ectopic environment.
Despite decades of research the pathogenesis of endometriosis remains poorly understood and therapies are limited. The disease is manifested as lesions containing ectopic endometrial epithelia and stroma that usually occur in the peritoneal cavity. According to Sampson's theory (1), endometriosis results from the transport of endometrial cells by retrograde menstruation into the peritoneal cavity where they attach to the peritoneum, proliferate and differentiate, and invade the underlying tissue. The assumption is that this process establishes small, early lesions, and subsequent growth and invasion lead to more progressive disease.

An alternative theory is that endometriosis results from metaplasia of Müllerian-type epithelium (2), by which cellular modification due to epigenetic or genetic alterations results in transformation of a specific Müllerian tissue type into endometrial tissue. Whatever the cause, the three different types of endometriotic lesions (i.e., peritoneal surface lesions, endometrioma, and deeply infiltrating lesions) are likely to have discrete aetiologies (3).

Development of new and more effective treatments for endometriosis will depend upon the determination of the molecular and cellular mechanisms that underlie the etiology of the disease. This has been hampered in part by the paucity of reproducible in vitro models of endometriosis. A number of different model systems have been exploited to study the function of cytokines, growth factors, peritoneal fluid, and immune factors in the pathogenesis of endometriosis. These include isolated epithelial and stromal cells (4-7), cultured menstrual efflux (8-11), transformed cell lines derived from peritoneal lesions (12), and cocultures of endometrial cells and peritoneal mesothelium (13-15).

One factor that may influence the severity of the disease is whether the cells undergo proliferation or differentiation in ectopic sites. Here, we report the use of an experimental culture system of endometriotic stromal cells to investigate the differentiation capacity of cells derived from different lesions. We establish the reliability and integrity of the system by determining expression with time in culture of endometrial markers in cultured stromal cell lines derived from peritoneal surface lesions, ovarian endometriomas, and deeply infiltrating lesions. We further determine the cell doubling times, as an indicator of proliferative capacity, of stromal cells derived from the different lesions, and women with and without endometriosis and the extent to which they retain the capacity to differentiate.

MATERIALS AND METHODS
Tissue Samples
All tissue samples were obtained with informed consent in accordance with the requirements of the Oxfordshire Research Ethics Committee. Samples of peritoneal surface lesions (n = 18), ovarian endometriomas (n = 29), and deeply infiltrating lesions (n = 14) were obtained from women 21–48 years old undergoing laparoscopy for pain (n = 13) or other benign indications (n = 28). Endometrium at different stages of the menstrual cycle was obtained by Pipelle biopsy from fertile women undergoing diagnostic laparoscopy or sterilization who were 20–49 years old with (n = 5) and without (n = 5) endometriosis (the latter comprising the normal control group), or by endometrial curettage of the bisected uteri obtained at hysterectomy for benign indications. Endometriotic samples were obtained from two of the five women with endometriosis from whom endometrium was obtained. None of the women had received hormonal medication in the preceding 3 months. Endometriotic tissue was
dissected away from the adjacent host tissue, and diagnosis was confirmed by histological examination.

**Isolation of Endometriotic and Endometrial Stromal Cells and Cell Culture**

Endometriotic and endometrial stromal cells were isolated as described previously (16). The purified stromal cells were plated into 75-cm² tissue culture flasks (10⁶ cells per flask) and maintained in Dulbecco's modified essential medium (DMEM; Invitrogen, United Kingdom) supplemented with 10% heat-inactivated fetal bovine serum and 50 IU/mL–50 μg/mL penicillin-streptomycin (DMEM complete) at 37°C in a humidified environment with 5% CO₂ in air. Stromal cell viability was assessed by Trypan blue exclusion and was similar in endometriotic and endometrial cell lines (approximately 84.2% and 86.9%, respectively). Stromal cells were used between passages 2 and 10. Human foreskin fibroblasts (FS2; a gift from P. Handford, Department of Biochemistry, University of Oxford) were used between passages 10 and 15. Human myometrial myocytes (a gift from S. Phaneuf, Department of Obstetrics and Gynaecology, University of Oxford) were used between passages 6 and 10 (17).

**Cytospins**

Cytospins (Shandon Southern Products Ltd., United Kingdom) of endometriotic and endometrial stromal cells were prepared at passages 2, 4, 6, and 10. Antibodies against cytokeratin, THY-1, vimentin, CD45, or CD68 (Table 1), were used with the alkaline phosphatase antialkaline phosphatase (APAAP) detection method (Dako, United Kingdom) according to the manufacturer's instructions. Cells (400 in each cytospin) were scored for positive or negative staining and the results were expressed as percentage positive.

**Immunocytochemistry**

Cultures of endometriotic and endometrial stromal cells were seeded onto 13-mm diameter glass coverslips size 0 (Chance, United Kingdom), cultured to confluence, and fixed and stained by the use of immunofluorescent techniques as described previously (16). Specific antigens (Table 1) were detected by incubation with antibodies to estrogen receptor-α (ER-α), progesterone receptor (PR), CD10, or mouse immunoglobulin G (IgG), followed by incubation with 15 μg/mL of donkey anti-mouse fluorescein isothiocyanate (FITC)-conjugated IgG (Jackson ImmunoResearch Laboratories, Inc., PA). Staining was assessed using a Leitz DMRBE microscope (Leica Corp., Germany) and Openlab imaging software (Improvision, United Kingdom).

**Cell Doubling Assays**

Subconfluent human endometriotic and endometrial stromal cells were plated into 25-cm² flasks (2 × 10⁵ cells/flask) in DMEM complete and incubated for 24, 48, 72, or 96 hours, dissociated with 1x trypsin-EDTA, and Trypan blue excluded cells were counted with a haemocytometer. Cell doubling time (T_G) was calculated as T_G = log(2)*T/log(Y) − log(X) with incubation time (T), final cell count (Y), and inoculation cell count (X). All cell doubling times were expressed as T_G ± SEM.

**In Vitro Decidualization of Stromal Cells**

Cultures of endometriotic and endometrial stromal cells were seeded into four-well plates (0.5 × 10⁵ cells per well) in DMEM/F12 (Invitrogen, United Kingdom) containing 10% charcoal-stripped calf serum (Sigma, United Kingdom) and grown until confluent. Decidualization was induced by the addition of 0.5 mM of 8-Bromoadenosine 3′:5′-cyclic Monophosphate (8-Br-cAMP; Sigma, United Kingdom). The morphology of the stromal cells was assessed, and duplicate samples of cells and the supernatants from cells cultured in
the presence or absence of 8-Br-cAMP were collected on days 3, 6, 9, 13, 16, and 20. Prolactin (PRL) and insulin-like growth factor-binding protein-1 (IGFBP-1) levels in the culture supernatants were measured with the PRL Immunolite Kit (DPC, United Kingdom) and DuoSet ELISA Kit (R&D Systems, United Kingdom), respectively, according to the manufacturer's instructions.

Cells were lysed with 50 mM of sodium hydroxide, and the total protein concentration was measured using the Coomassie Plus assay (Pierce, United Kingdom) at a wavelength of 600 nm using a MRX Microplate Reader (Dynex, United Kingdom). Levels of secreted PRL and IGFBP-1 were normalized to the amount of total protein present in each well and values were expressed as ng ± SEM/100 μg total protein. The detection levels of PRL and IGFBP-1 were 0.5 ng/mL and 60 μg/mL, respectively.

**Statistical Analyses**

The decidualization responses were subjected to one-way analysis of variance (ANOVA) followed by a Tukey's Multiple Comparison posttest. Results with an α level of <0.05 were considered statistically significant.

**RESULTS**

**Endometriotic and Endometrial Stromal Cells Retain Endometrial Markers in Culture**

In the absence of a specific marker for endometriosis, a number of cellular markers were used to confirm the stromal phenotype and the exclusion of contaminating cells such as smooth muscle, endothelial, and haematopoietic cells (Table 1). Immunohistology performed on sections of endometrium and endometriosis confirmed that glandular epithelium stained positive for cytokeratin 18, and endometrial and endometriotic stromal cells were cytokeratin-negative, and positive for vimentin and THY-1 (data not shown), thus confirming previous reports (5-7, 12). In addition, expression of the common acute lymphoblastic leukemia antigen CD10, which, according to recent reports, is expressed in endometrial and endometriotic stroma (17), was investigated.

Cytospins were prepared from endometriotic and endometrial stromal cell lines at passages 2, 4, 6, and 10, and screened with antibodies to cytokeratin, THY-1, vimentin, CD45, or CD68 (Table 1) to assess the stability of the stromal cell phenotype over time in culture (Fig. 1). Endometriotic stromal cells were >95% THY-1 and vimentin-positive with <2% contaminating epithelial and bone-marrow-derived cells, as revealed by staining with cytokeratin and CD45, respectively, at passage 2. This pattern was retained throughout the culture period up to passage 10 and was comparable to the expression of markers by cultured endometrial stromal cells from women with and without endometriosis.

Endometriotic tissue in situ is thought to be hormone-responsive. We therefore investigated the expression of hormone receptors in the cultured endometriotic and endometrial stromal cell lines. Stromal cell lines derived from ovarian endometriomas, peritoneal surface lesions, and deeply infiltrating lesions; endometrial stromal cells from women with and without endometriosis (n = 3 each) were stained for ER-α, PR and CD10 at primary culture, as well as passages 2, 4, and 6 (Fig. 2). Stromal cells derived from peritoneal surface and deeply infiltrating lesions retained expression of ER-α and PR with passaging.

Ovarian-endometrioma-derived stromal cells displayed a low expression of ER-α at primary culture, which was subsequently lost with passaging, and retained PR expression up to passage 6. Endometrial stromal cells from women with and without endometriosis retained expression of ER-α and PR with passaging over the period monitored. Furthermore,
cultured stromal cells derived from all of the endometriotic lesions and endometrial tissue samples expressed CD10.

Endometriotic Stromal Cells Divide More Rapidly Than Endometrial Stromal Cells

Normal human cells can have different growth characteristics in vitro depending on the donor, donor age, and origin of tissue (18). We therefore investigated the growth properties of the three different types of endometriotic lesions and endometrium from women with and without endometriosis (Fig. 3). Stromal cells isolated from endometrium from women without and with endometriosis had similar cell doubling times of 3.9 ± 0.9 days and 3.2 ± 0.7 days respectively. These cell doubling times were comparable to stromal cells derived from ovarian endometrioma and peritoneal surface lesions (3.0 ± 0.4 days and 2.7 ± 0.2 days, respectively). Stromal cells isolated from deeply infiltrating lesions had a significantly shorter cell doubling times of 1.9 ± 0.4 days compared with those isolated from endometrium from women with and without endometriosis and endometrioma.

Endometriotic and Endometrial Stromal Cells From Women With Endometriosis Exhibit a Reduced Capacity for Decidualization

Endometrial stromal cells undergo decidualization in response to steroid hormones during the late secretory stage of the menstrual cycle and early pregnancy, and can be induced to decidualize in vitro (19). We investigated whether endometriotic stromal cells retain this capacity for differentiation in response to 8-Br-cAMP, as assessed by morphology and measurement of PRL and IGFBP-1 production.

We tested stromal cells derived from ovarian endometriomas, peritoneal surface lesions, and deeply infiltrating lesions, as well as endometrial stromal cell lines from fertile women with and without endometriosis (n = 5 each), FS2 cells, and human myometrial cells. Cells derived from endometrial tissues exhibited a characteristic change in morphology from bipolar fibroblast to polygonal decidual cell from day 3 onward (Fig. 4). Endometriotic stromal cells also exhibited morphological changes, but these changes were not evident until day 6.

We measured PRL and IGFBP-1 levels as a more sensitive quantitative assessment of decidualization (Fig. 5). The levels of PRL and IGFBP-1 secretion in supernatants of endometrial stromal cells from women with and without endometriosis increased until day 6, were then lower on day 9, and subsequently increased until day 20. In contrast, PRL and IGFBP-1 secretion in supernatants of endometriotic stromal cells, although significantly lower than endometrial cells, increased without a peak until day 20.

Stromal cells derived from ovarian endometriomas, peritoneal surface and deeply infiltrating lesions, foreskin fibroblasts, and myocytes secreted similar PRL levels into the supernatants (at day 6: 1.7 ± 0.5, 1.7 ± 0.5, 1 ± 0.1, 3.8 ± 0.1, and 1 ± 0.04 ng/100 μg protein, respectively) (Fig. 5A and 5B). Cumulative PRL levels were also comparable (12.8 ± 0.4, 15.3 ± 0.4, 13.2 ± 0.5, 18.7 ± 0.5 and 16.1 ± 0.8 ng/100 μg protein, respectively). Levels of IGFBP-1 in culture supernatants from stromal cells derived from ovarian endometriomas were at least twofold higher than those from peritoneal surface and deeply infiltrating lesions (at day 6: 80.8 ± 12.9, 43.01 ± 17.5 and 12.1 ± 3.2 ng/100 μg protein, respectively) (Fig. 5C). Foreskin fibroblasts did not secrete detectable levels of IGFBP-1. Cumulative IGFBP-1 secretion by stromal cells derived from ovarian endometriomas, peritoneal surface and deeply infiltrating lesions, and myocytes was 747.1 ± 24.9, 244.6 ± 6.7, 127.5 ± 4 and 564.2 ± 24.7 ng/100 μg protein, respectively.

Levels of PRL in endometrial stromal cell supernatants from normal controls were twofold higher than in those from women with endometriosis (at day 6: 25.7 ± 3.8 ng/100 μg protein
and 14.4 ± 2.4 ng/100 μg protein, respectively) (Fig. 5B). Levels of IGFBP-1 were also higher in endometrial stromal cell supernatants from women without endometriosis than those from affected women (905 ± 94 and 651 ± 152 ng/100 μg protein, respectively, at day 6) (Fig. 5D). Cumulative PRL and IGFBP-1 levels were reduced in supernatants from stromal cells derived from women with endometriosis (56 ± 2 and 1923 ± 79.9 ng/100 μg protein, respectively) compared with those derived from unaffected women (126.4 ± 4 and 4690 ± 132.3 ng/100 μg protein, respectively). The levels of PRL and IGFBP-1 from endometriotic and endometrial stromal cells in the absence of 8-Br-cAMP was close to the minimum the detection level of 0.5 ng/mL and 60 pg/mL in all samples.

The levels of PRL and IGFBP-1 in supernatants from stromal cells derived from ovarian endometriomas, peritoneal surface lesions, and deeply infiltrating lesions correlated well (r² = 0.8540, r² = 0.6178, and r² = 0.7886, respectively), and in endometrial stromal cells from women with and without endometriosis (r² = 0.9614 and r² = 0.6945, respectively).

DISCUSSION

Endometriosis is a significant women's healthcare problem worldwide, and determination of the molecular and cellular process that lead to endometriosis remains a challenging clinical and scientific problem. The manipulation of cell lines derived from endometriotic lesions offers a valuable experimental system with which to study the molecular and cellular processes underlying the pathogenesis of the disease. However, it is important to demonstrate that such cell lines retain endometrial integrity if they are to be a useful tool for investigating how processes that are likely to be involved in the pathogenesis of the disease, such as proliferation and differentiation, are regulated in endometriotic cells. Here, we demonstrate that [1] cultured stromal cells derived from the three different types of endometriotic lesions exhibit sustained expression of endometrial markers in in vitro culture; [2] compared with endometrial stromal cells, endometriotic stromal cells from deeply infiltrating lesions exhibit increased proliferative potential; and [3] stromal cells derived from endometriotic lesions and endometrium from women with endometriosis have a reduced capacity for decidualization.

Previously, various markers have been used to confirm the purity of isolated endometriotic cells including cytokeratin 18 and vimentin, negative markers such as van Willebrand factor VIII, and the leukocyte markers CD3, CD11b, CD14, and CD45 (6, 7, 20). The cell lines from the three different types of lesions we describe here retain expression of vimentin, and lack cytokeratin, CD45, and CD68 with time in culture. In addition, expression of THY-1, a marker of endometrial stromal fibroblasts (5, 21), and CD10, a distinguishing marker for endometriosis (22), in stromal cells from the three types of endometriotic lesions is also sustained with passage in culture.

Endometriosis occurs in women during their reproductive years, and the condition is likely to be hormone-dependent. We observe expression of ER-α in stromal cells derived from peritoneal surface and deeply infiltrating lesions and expression of PR in stromal cells derived from all endometriotic lesions.

Hormone receptor levels in endometriotic lesions in vivo are reportedly lower than in normal endometrium, and the cycle-specific changes of hormone receptor expression observed in the endometrium are not always evident in endometriotic lesions (23-25). Thus, the pattern of hormone receptor expression we observe in the endometriotic stromal cell lines is consistent with that in vivo.

Differentiation of endometrial stromal cells into predecidual cells occurs in the late secretory phase of the cycle (26, 27). We investigated the possibility that endometrial cells capable of

Fertil Steril. Author manuscript; available in PMC 2006 October 30.
forming an endometriotic lesion are reprogrammed and lose their capacity for
differentiation. Our experimental data suggest that stromal cells derived from ovarian
demetriomas, peritoneal surface lesions, and deeply infiltrating lesions retain the capacity
to differentiate morphologically and to secrete biochemical markers of decidualization, PRL,
and IGFBP-1, but at a much lower level than endometrial stromal cells. Decidualization of
endometriotic stromal cells has been observed in women (28-31) and nonhuman primates
(32-34) in vivo. In addition, PRL and IGFBP-1 levels in peritoneal fluid and serum have
been found previously to be similar in women with and without endometriosis (35-37).

These reports suggest that, although morphological changes associated with decidualization
occur in endometriotic lesions, levels of biochemical markers are either not increased or are
being cleared rapidly from the bodily fluids.

Although endometriotic lesions are benign, they share certain characteristics with
malignancies, indicating that some of the processes involved in the aetiology of both
pathologies may be similar. We show that, in common with tumors, endometriotic stromal
cells have a reduced capacity for cellular differentiation. We speculate that this in turn may
influence the capacity for proliferation of the cells in the ectopic environment.

The maximum number of cell doublings in endometrial stromal cells is variable but is
remarkably high for cells derived from adult human tissues and may reflect the
extraordinary proliferative capacity of the endometrium (18, 38). It has been reported
previously that endometrial stromal cells have a doubling time of 4–5 days and stromal cells
derived from ovarian endometriosis 5–6 days depending on the culture conditions (7).
However, we observe shorter cell doubling times for endometrial stromal cells (3–4 days) in
our culture conditions. Endometriotic stromal cells have a further reduced doubling time (3
days) with deeply infiltrating endometriotic stromal cells having the shortest doubling time
(2 days), which is comparable to previously reported transformed endometriotic cells (12).
These observations support the notion that the proliferative capacity of stromal cells is
increased in the ectopic environment.

We report that levels of prolactin and IGFBP-1 secreted by decidualizing endometrial
stromal cells derived from women with endometriosis are reduced in comparison with
women without endometriosis. Recent studies demonstrate that the endometrium from
women with endometriosis displays morphologically normal but biochemically abnormal
responses during the window of implantation (reviewed in [39] and references therein). In
this context, abnormal remodeling of the extracellular matrix of endometrial stroma and
aberrant integrin expression have been associated with implantation defects. Our data
suggest that in women with endometriosis, the signaling cascade leading to decidualization
might be impaired, potentially decreasing the biochemical maturation required for correct
implantation.

In conclusion, we have shown that stromal cells derived from different endometriotic lesions
exhibit sustained expression of endometrial markers with culture and decreased capacity for
differentiation. We speculate that the reduced capacity for differentiation of endometriotic
cells may be associated with an increased capacity for survival and proliferation of stromal
cells in the ectopic environment. The characterized endometriotic stromal cell cultures we
describe provide a relevant experimental system that will allow further dissection of the
molecular basis of the processes involved in the pathogenesis of distinct endometriotic
lesions.
Acknowledgments

This research was funded by a studentship (to P.K.) from The National Endometriosis Society, The Wellcome Trust, and The Medical Research Council. We are extremely grateful to David Barlow, Enda McVeigh, and the clinical staff of the Women’s Centre, John Radcliffe Hospital for their valuable contribution to this work.

REFERENCES


FIGURE 1.
Expression of markers in cultured stromal cells. Quantitative immunocytochemistry of tissue marker expression in endometriotic and endometrial stromal cells at passages 2, 4, 6, and 10. Data are expressed as percentage positive cells and bars represent mean ± SEM. Endometriotic stromal cells express >95% THY-1 and vimentin and <2% cytokeratin, CD45, and CD68. The level of purity and tissue marker expression is comparable to endometrial controls and remained stable with time in culture. (PSL, n = 8) peritoneal surface lesion; (DIL, n = 8) deeply infiltrating lesion; (Eoma, n = 8) ovarian endometrioma; (EME, n = 3) endometrium from women with endometriosis; (EM, n = 3) endometrium; and (P) passage of cells.
FIGURE 2.
Expression of hormone receptors and CD10 in endometriotic and endometrial stromal cells. Endometriotic stromal cells (n = 3 each) from peritoneal surface lesions (A–D), deeply infiltrating lesions (E–H), ovarian endometrioma (I–L), and endometrial stromal cells (n = 3 each) from women with (M–P) and without endometriosis (Q–T) were grown on glass coverslips to confluence and stained for ER-α (A, E, I, M, Q), PR (B, F, J, N, R), and CD10 (C, G, K, O, S) expression and with the negative control mouse IgG (D, H, L, P, T) using immunofluorescent technique. The PSL and DIL stromal cell expressed ER-α at each passage tested, whereas Eoma stromal cells expressed ER-α only at primary culture. Expression of PR was detectable in all three endometriotic lesions at each passage tested. Endometrial stromal cells expressed both ER-α and PR. Endometriotic and endometrial stromal cells expressed CD10 in the cytoplasm. PSL, peritoneal surface lesion; DIL, deeply infiltrating lesion; Eoma, ovarian endometrioma. Magnification ×20, scale bar 100 μm.
FIGURE 3.
Growth curve of endometriotic and endometrial stromal cells. Endometriotic and endometrial stromal cells were plated in DMEM complete, and total cell counts were determined after 24, 48, 72, and 96 hours of culture. (open circle, PSL, n = 3) peritoneal surface lesion; (diamond, DIL, n = 3) deeply infiltrating lesion; (filled circle, Eoma, n = 3) ovarian endometrioma; (open square, EME, n = 3) endometrium from women with endometriosis; (filled square, EM, n = 4) endometrium.
FIGURE 4.
Morphology of in vitro decidualized endometriotic and endometrial stromal cells. Confluent stromal cells from peritoneal surface lesions (A, F), deeply infiltrating lesions (B, G), ovarian endometrioma (C, H), and endometrial stromal cells from women with (D, I) and without endometriosis (E, J) were treated with or without 0.5 mM of 8 Br-cAMP for 9 days. Endometriotic stromal cells (A–C) underwent morphological changes from bipolar fibroblasts into polygonal decidual cells, but these were delayed (day 6 onward) and not as widespread compared with endometrial stromal cells that exhibited the characteristic change in morphology from day 3 onward (D, E). Untreated cells (F–J) retained a fibroblast-like, spindle shape appearance. Magnification ×10, scale bar 100 μm.
FIGURE 5. Time-dependent secretion of PRL and IGFBP-1 in endometriotic and endometrial stromal cells. Endometriotic stromal cells (A, C) and endometrial stromal cells (B, D) were allowed to decidualize in vitro, in response to 0.5 mM of 8-Br-cAMP for 20 days. The PRL and IGFBP-1 secretion by stromal cells into supernatants was measured every 3–4 days and normalized to total protein contents. Secretion of PRL was similar by all three types of endometriotic stromal cells, dermal fibroblasts, and myometrial myocytes. Endometrial stromal cells secreted tenfold more PRL in comparison with endometriotic stromal cells (*P<0.001 throughout culture period). The PRL secretion by endometrial stromal cells from women with endometriosis was also reduced by half in comparison with normal endometrial stromal cells (*P<0.05, B). (C) Secretion of IGFBP-1 was >threefold higher in stromal cells derived from ovarian endometrioma compared with peritoneal surface lesions and deeply infiltrating lesions. The difference between endometrioma and deeply infiltrating lesions was significant throughout the culture period. (D) Endometrial stromal cells secreted 20-fold more IGFBP-1 in comparison with endometriotic stromal cells (*P<0.001 throughout the culture period). Secretion of IGFBP-1 was also lower in endometrial stromal cells from women with endometriosis compared with those from women without endometriosis (*P<0.05). (○, PSL, n = 5) peritoneal surface lesion; (diamond, DIL, n = 5) deeply infiltrating lesion; (filled circle, Eoma, n = 5) ovarian endometrioma; (asterisk, FS2, n = 1) foreskin...
fibroblasts; (closed square, EM, n = 5) endometrium; (open square, EME, n = 5)
endometrium from women with endometriosis; (triangle, MC, n = 1) myometrial myocytes.
### TABLE 1

Details of the antibodies used to detect marker expression.

<table>
<thead>
<tr>
<th>Marker</th>
<th>Clone</th>
<th>Working dilution</th>
<th>Source</th>
<th>Reference no.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytokeratin 18</td>
<td>JMB2</td>
<td>1:2</td>
<td>In-house</td>
<td>(18)</td>
</tr>
<tr>
<td>THY-1</td>
<td>F 15-42-1</td>
<td>7.6 μg/mL</td>
<td>Serotec</td>
<td>(19)</td>
</tr>
<tr>
<td>Vimentin</td>
<td>V9</td>
<td>1:100</td>
<td>Sigma</td>
<td>(20)</td>
</tr>
<tr>
<td>CD45</td>
<td>F 10/89/4</td>
<td>0.4 μg/mL</td>
<td>Serotec</td>
<td>(18)</td>
</tr>
<tr>
<td>CD68</td>
<td>Ki-M6</td>
<td>10 μg/mL</td>
<td>Serotec</td>
<td>(21)</td>
</tr>
<tr>
<td>Estrogen receptor α</td>
<td>1 D5</td>
<td>14 mg/mL</td>
<td>Dako</td>
<td>(22)</td>
</tr>
<tr>
<td>Progesterone receptor</td>
<td>PgR636</td>
<td>4.7 μg/mL</td>
<td>Dako</td>
<td>(23)</td>
</tr>
<tr>
<td>CD10</td>
<td>MEM78</td>
<td>1:10</td>
<td>Novocastra</td>
<td>(24)</td>
</tr>
<tr>
<td>Mouse IgG</td>
<td>2T8-2F5</td>
<td>10 μg/mL</td>
<td>Coulter</td>
<td></td>
</tr>
</tbody>
</table>

*Note: IgG = immunoglobulin G.*